Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Michael C. Ostrowski

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2948-6297; OpenAlex author ID A5040645408; NIH RePORTER profile ID 1858162. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 2)
Trials
0
Grants
2
Labs led
2
Collaborators
42
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 2 papers · 2016: none · 2017: 1 paper, 1 grant · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 3 papers, 1 grant · 2026: 1 paper

Papers 12

  1. KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Co-author DOI 10.1158/0008-5472.can-25-2630↗
  2. Pancreatic Cancer Induces Population-Specific Switching of Myosin Isoforms and Discrete Activation of Cachexia Genes in Skeletal Muscle Myocytes Co-author DOI 10.1101/2025.09.01.673500↗
  3. Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Surviva… Co-author DOI 10.1200/jco-25-01631↗
  4. Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cac… Co-author DOI 10.1200/jco.23.01965↗
  5. Optimization of a mouse model of pancreatic cancer to simulate the human phenotypes of metastasis and cachexia. Co-author DOI 10.1186/s12885-024-12104-0↗
  6. Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis. Co-author DOI 10.1080/21541248.2021.1906621↗
  7. STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer. Last author DOI 10.26508/lsa.202201460↗
  8. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-311585↗
  9. Generation of a pancreatic cancer model using a Pdx1-Flp recombinase knock-in allele. Last author DOI 10.1371/journal.pone.0184984↗
  10. Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer Co-author DOI 10.1186/2051-1426-3-s2-p366↗
  11. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Co-author DOI 10.18632/oncotarget.6332↗
  12. Genetically engineered murine pancreatic cancer models approximate immunophenotypic properties of human patients Co-author DOI 10.1186/2051-1426-1-s1-p163↗

Grants 2

  1. Project 3 – Stromal derived IL-6/STAT3 signaling in the development and progression of PDAC P01CA236778↗
  2. Stromal IL -6/Jak-STAT Signaling and Pancreatitis R21AI124687↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teresa A Zimmers · 6 shared papers, 1 shared grant, 2015–2025 · strength 1.47
  2. Denis C. Guttridge D · 6 shared papers, 2022–2026 · strength 1.17
  3. Martin John Romeo · 2 shared papers, 1 shared grant, 2022–2025 · strength 0.93
  4. Jian Ouyang · 1 shared grant, 2025 · strength 0.61
  5. Denis C Guttridge · 1 shared grant, 2025 · strength 0.61
  6. Leonidas G. Koniaris · 1 shared grant, 2025 · strength 0.61
  7. Gregory B. Lesinski · 5 shared papers, 1 shared grant, 2013–2022 · strength 0.60
  8. Victoria K. Spadafora · 2 shared papers, 2024–2026 · strength 0.42
  9. Katherine R. Pelz · 2 shared papers, 2025 · strength 0.41
  10. Susann Theile · 2 shared papers, 2025 · strength 0.41
  11. Dorte Lisbet Nielsen · 2 shared papers, 2025 · strength 0.41
  12. Julia Sidenius Johansen · 2 shared papers, 2025 · strength 0.41
  13. Olav Faisal Dajani · 2 shared papers, 2025 · strength 0.41
  14. Inna Markovna Chen · 2 shared papers, 2025 · strength 0.41
  15. Jason Robert Pitarresi · 5 shared papers, 2015–2022 · strength 0.33
  16. Lu Han · 2 shared papers, 2022–2026 · strength 0.33
  17. G. Aaron Hobbs · 2 shared papers, 2022–2026 · strength 0.33
  18. Julia E. Lefler · 2 shared papers, 2022 · strength 0.25
  19. Catherine B. MarElia · 2 shared papers, 2022 · strength 0.25
  20. Brittany R. Counts · 1 shared paper, 2025 · strength 0.23
  21. David F. Kashatus · 1 shared paper, 2026 · strength 0.21
  22. Christabelle Rajesh · 1 shared paper, 2026 · strength 0.21
  23. Rachel A. Burge · 1 shared paper, 2026 · strength 0.21
  24. Thomas B. McFall · 1 shared paper, 2026 · strength 0.21
  25. Christopher M Counter · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.